专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240166736A1 ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY 审中-公开
公开(公告)号：US20240166736A1
公开(公告)日：2024-05-23
申请号：US18396461
申请日：2023-12-26
申请人： Astellas Pharma Inc. , National Cancer Center
发明人： Yoshiyuki TENDA , Masatoshi YURI , Daisuke YAMAJUKU , Takeshi TSUTSUMI , Yuko KUSUZAKI , Hiroki SASAKI , Fumiko CHIWAKI , Masayuki KOMATSU
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00
CPC分类号： C07K16/28 , A61P35/00 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/622 , C07K2317/732 , C07K2317/76
摘要： An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

2. 发明公开

US20240209108A1 ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY 审中-公开
公开(公告)号：US20240209108A1
公开(公告)日：2024-06-27
申请号：US18556606
申请日：2022-04-21
申请人： Astellas Pharma Inc. , National Cancer Center
发明人： Yoshiyuki TENDA , Masatoshi YURI , Shigenori YAGI , Yoshiki SATAKE , Kazunori HIRAYAMA , Hiroki SHIRAI , Hiroki SASAKI , Fumiko CHIWAKI , Masayuki KOMATSU
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00
CPC分类号： C07K16/2878 , A61P35/00 , C07K16/28 , A61K2039/505 , C07K2317/31 , C07K2317/622
摘要： An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.
An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon γ by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.

3. 发明公开

US20230348587A1 ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODY 审中-公开
公开(公告)号：US20230348587A1
公开(公告)日：2023-11-02
申请号：US17639783
申请日：2021-11-15
申请人： Astellas Pharma Inc. , National Cancer Center
发明人： Yoshiyuki TENDA , Masatoshi YURI , Daisuke YAMAJUKU , Takeshi TSUTSUMI , Yuko KUSUZAKI , Hiroki SASAKI , Fumiko CHIWAKI , Masayuki KOMATSU
IPC分类号： C07K16/28 , A61P35/00
CPC分类号： C07K16/28 , A61P35/00 , C07K16/2809 , A61K2039/505
摘要： An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

4. 发明申请

US20190248904A1 NOVEL ANTI-HUMAN BDCA-2 ANTIBODY 审中-公开
公开(公告)号：US20190248904A1
公开(公告)日：2019-08-15
申请号：US16384811
申请日：2019-04-15
申请人： Astellas Pharma Inc.
发明人： Shinsuke NAKAO , Masayuki ITO , Yoshiyuki TENDA
IPC分类号： C07K16/28
CPC分类号： C07K16/2851 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2510/00
摘要： [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.[Means for Solution] The present inventors have investigated anti-human BDCA-2 antibodies, and as a result, they have provided an anti-human BDCA-2 antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 109 of SEQ ID NO: 4, a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 6 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 8, and a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 122 of SEQ ID NO: 10 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 12.

5. 发明申请

US20160319025A1 NOVEL ANTI-HUMAN BDCA-2 ANTIBODY 审中-公开
标题翻译：新型抗人BDCA-2抗体
公开(公告)号：US20160319025A1
公开(公告)日：2016-11-03
申请号：US15107660
申请日：2014-12-22
申请人： ASTELLAS PHARMA INC.
发明人： Shinsuke Nakao , Masayuki ITO , Yoshiyuki TENDA
IPC分类号： C07K16/28
CPC分类号： C07K16/2851 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2510/00
摘要： [Problem] Provided is an anti-human BDCA-2 antibody for preventing or treating an autoimmune disease by binding to a human BDCA-2 to control the function of a plasmacytoid dendritic cell through human BDCA-2.[Means for Solution] The present inventors have investigated anti-human BDCA-2 antibodies, and as a result, they have provided an anti-human BDCA-2 antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 109 of SEQ ID NO: 4, a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 6 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 8, and a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 122 of SEQ ID NO: 10 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 12.
摘要翻译： [解决方案]本发明人研究了抗人BDCA-2抗体，结果提供了抗人BDCA-2抗体，其包含由氨基酸序列的氨基酸序列组成的重链可变区 SEQ ID NO：2的1〜120和由SEQ ID NO：4的氨基酸编号1〜109的氨基酸序列组成的轻链可变区，由氨基酸序列的氨基酸序列组成的重链可变区 SEQ ID NO：6的1〜120和由SEQ ID NO：8的氨基酸编号1〜108的氨基酸序列组成的轻链可变区和由氨基酸的氨基酸序列组成的重链可变区 SEQ ID NO：10的数字1〜122和由SEQ ID NO：12的氨基酸编号1〜108的氨基酸序列构成的轻链可变区。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式